GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Digipath Inc (OTCPK:DIGP) » Definitions » Debt-to-EBITDA

Digipath (Digipath) Debt-to-EBITDA : -10.31 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Digipath Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Digipath's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.35 Mil. Digipath's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Digipath's annualized EBITDA for the quarter that ended in Dec. 2023 was $-0.23 Mil. Digipath's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -10.31.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Digipath's Debt-to-EBITDA or its related term are showing as below:

DIGP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.13   Med: -1.27   Max: -0.45
Current: -10.13

During the past 13 years, the highest Debt-to-EBITDA Ratio of Digipath was -0.45. The lowest was -10.13. And the median was -1.27.

DIGP's Debt-to-EBITDA is ranked worse than
100% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.005 vs DIGP: -10.13

Digipath Debt-to-EBITDA Historical Data

The historical data trend for Digipath's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Digipath Debt-to-EBITDA Chart

Digipath Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.45 -1.27 -9.44 -1.22 -7.22

Digipath Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.22 -14.95 -10.73 -7.07 -10.31

Competitive Comparison of Digipath's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Digipath's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Digipath's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Digipath's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Digipath's Debt-to-EBITDA falls into.



Digipath Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Digipath's Debt-to-EBITDA for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.29 + 0) / -0.317
=-7.22

Digipath's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.35 + 0) / -0.228
=-10.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Digipath  (OTCPK:DIGP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Digipath Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Digipath's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Digipath (Digipath) Business Description

Traded in Other Exchanges
N/A
Address
6450 Cameron Street, Suite 113, Las Vegas, NV, USA, 89118
DigiPath Inc is engaged in providing pharmaceutical-grade analysis and testing cannabis education and training and brings unbiased cannabis news coverage to the cannabis industry. It screens medicinal cannabis for potentially harmful contaminants, including solvents, pesticides, mold and yeast, heavy metals such as mercury, arsenic, cadmium, and others. It also tests cannabis for its quality, potency, and cannabinoid and terpene profiles, which determine the suitability of specific cannabis strains for the treatment of specific ailments.
Executives
A Stone Douglass director 10200 WILLOW CREEK ROAD, SAN DIEGO CA 92131
Edmond Defrank director 19360 RINALDI STREET, #448, NORTHRIDGE CA 91326
Kyle Remenda officer: Chief Executive Officer 111-2532 SHORELINE DRIVE, LAKE COUNTRY A1 V4V2R6
Dennis Hartmann director 1600 CAMDEN AVENUE, NO. 103, LOS ANGELES CA 90025
Bruce I Raben director 430 VICTORIA TERRACE, RIDGEFIELD NJ 7657
Cindy Sue Orser director 4507 APPLE WAY, BOULDER CO 80301
Alfredo Axtmayer director 287 PAYNE DRIVE, CHESHIRE CT 06410
Joseph J Bianco director 611 BROADWAY,, SUITE 307, NEW YORK NY 10012
Todd A Peterson officer: Chief Financial Officer 3608 MALLARDWOOD DRIVE, LAS VEGAS NV 89129
Joe D Tanner director 28720 ROADSIDE DRIVE, SUITE 128, AGOURA HILLS CA 91301
Raw Alternative, Llc 10 percent owner 16030 VENTURA BLVD. SUITE 380, ENCINO CA 91436
Todd Denkin director, officer: President C/O PHOTOTRON, INC., 20259 VENTURA BLVD., WOODLAND HILLS CA 91364
Barbee Denny Barbee 10 percent owner 3105 EAST CENTRAL, #114, WICHITA KS 67214
Eric Stoppenhagen director, 10 percent owner, officer: CFO 8908 SPLITARROW DRIVE, AUSTIN TX 78717